Skip to content
Catalyst

PapersPMID:9892253

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.

Archives of general psychiatry1999The record ↗

  1. Finding, very limited evidencelowersPANSS negative subscale score

What moved

1 findingHow to read these marks →
  • “Glycine administration resulted in (1) a significant (P<.001) 30%+/-16% reduction in negative symptoms, as measured by the PANSS, and (2) a significant (P<.001) 30%+/-18% improvement in the BPRS total scores.”
    Study
    crossover
    Dose studied
    0.8 g/kg per day glycine added to ongoing antipsychotic medication
    Population
    Twenty-two treatment-resistant schizophrenic patients with enduring negative symptoms, glycine added to ongoing antipsychotic medication in a double-blind placebo-controlled crossover

Study record

Design
crossover trial
Species
human
Population
treatment-resistant schizophrenic patients with enduring negative symptoms on ongoing antipsychotic medication
Participants
22
Comparator
placebo
Duration
42 days
Endpoints measured
6
Declined
this platform holds no node for the endpoint